Jun Bei Liu is the founder of Ten Cap, and lead portfolio manager of its flagship fund, the Ten Cap Alpha Plus fund. She is also a popular media personality and a highly sought after public speaker about her investment views. She has been appointed a Core Fund Manager for Hearts and Minds Investments and volunteers for the Raise Foundation Board. Jun Bei is fluent in Mandarin and English after emigrating to Australia from China at 16. She completed a commerce degree at the University of New South Wales, followed by a number of finance credentials including GAICD and CFA. Connect with Jun Bei on LinkedIn.
Friends With Money #237: 2026 equities preview
After a volatile year, can Australian shares bounce back in 2026 - and which sectors could surprise? Jun Bei Liu joins us on the Friends With Money podcast to share her outlook.
Is now the time to buy Sigma Healthcare?
After years of underperformance, the recent Chemist Warehouse merger may have completely changed the game for Sigma Healthcare.
How Tabcorp is betting on a new era
For decades, Tabcorp has been synonymous with Australian betting, but the company is now fighting for relevance in a fiercely competitive, digital-first market.
Tuas delivers stunning growth for ASX investors
What happens when one of Australia's most successful and mysterious telecom founders sets his sights on Singapore? Look no further than Tuas (ASX:TUA).
Why Seek shares should be in your portfolio
Earnings are up, pricing power is strong - SEEK is proving resilient, even as job ads stay soft across Australia and New Zealand.
Why A2 Milk is a strong buy for your portfolio
A2 Milk has quietly been one of the best-performing large caps on the ASX this year, up over 30%, yet many investors are underestimating the turnaround that's underway.
Why you need REA Group in your portfolio
If you're looking for exposure to the Australian housing recovery, REA Group - the operator of realestate.com.au - is showing no signs of slowing down.
Betr’s big bet: Sportsbetting app raises eyebrows
As Australia's wagering industry becomes increasingly crowded and regulated, one player is doing things differently.
Is now the time to buy, hold or sell ResMed shares?
The arrival of weight-loss drugs like Ozempic rattled ResMed shareholders but so far the fear has been misplaced, writes Jun Bei Liu.
Should you buy, hold or sell Fisher & Paykel Healthcare?
Headquartered in Auckland, Fisher & Paykel Healthcare has translated its robust sales growth into even stronger earnings growth.
